StockNews.AI
APYX
StockNews.AI
147 days

Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

1. Renuvion won NewBeauty's 'Best Minimally Invasive Skin Tightener' award. 2. It's the only FDA-cleared device post-liposuction for skin tightening. 3. Consumer interest in loose skin has surged by 168.7% in 2024. 4. Renuvion boasts over 90 clinical publications supporting its effectiveness. 5. Surgeons increasingly trust Renuvion for body contouring solutions.

6m saved
Insight
Article

FAQ

Why Bullish?

Recognition by NewBeauty enhances Renuvion's brand credibility, likely increasing sales. Historical trends show awards positively affect stock performance for medical companies.

How important is it?

Award recognition could lead to increased sales and market presence, affecting investor confidence.

Why Short Term?

Immediate boost in consumer interest and brand visibility can drive sales quickly.

Related Companies

APYXMDGSPLX
Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin , /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. The NewBeauty Awards franchise is a leading and trusted program in the beauty space. The award winners represent effective solutions to consumers' biggest beauty interests, concerns, and trends. Renuvion is the only device FDA-cleared for use after liposuction and is raising the bar for what consumers should expect from body contouring treatments. With more than 90 evidence-based clinical publications and long-lasting durable results from just one treatment, Renuvion has garnered a global fan base of consumers and plastic surgeons alike. This recognition comes at a pivotal time as consumers increasingly focus on the issue of loose and lax skin. According to Spate research, searches for "sagging skin" have surged by 168.7% in 2024 compared to the previous year.2 "We are proud to have Renuvion's game-changing technology receive this accolade by a trusted authority in the aesthetic space," said Charlie Goodwin, President, and CEO of Apyx Medical. "Thousands of plastic surgeons rely on Renuvion, the #1 body contouring technology trusted by doctors3, to provide an effective solution to the challenges of loose skin." NewBeauty editors tested thousands of products leading up to the 15th annual Awards Issue with the goal of selecting the most innovative beauty products, treatments, and trends. NewBeauty editors also collaborate with board-certified doctors and medical experts to determine the most effective, results-driven in-office treatments and post-procedure essentials. To learn more about how Renuvion can address skin concerns, and find a provider near you, visit www.Renuvion.com. 1. Renuvion is intended for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue. Renuvion is intended for the coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.2. https://www.personalcareinsights.com/news/spate-search-data-suggests-innovative-opportunities-to-target-saggy-skin-and-nose-bumps.html 3. In an independent survey by Wakefield Research of 200 unaffiliated board certified or eligible cosmetic and plastic surgeons in the US where 4 out of 5 surgeons agree. About Apyx Medical Corporation: Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com  Media Contact: Kaplow Communications [email protected]  SOURCE Renuvion WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News